NCT06411457Recruiting
SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer
Single-arm, Multi-center Phase II Clinical Study of SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Breast Cancer
- Drug/Device/Intervention
- SHR-A1811+Adebrelimab
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Location
- Beijing, China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- May 16, 2024
- End date
- May 01, 2026
- Enrollment
- 20 participants
Primary outcome
ORR
Summary
To evaluate the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen
 in HER2 low-expressing metastatic breast cancer
ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedMalignant neoplasm: Breast, unspecifiedOther carcinoma in situ of breast
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06411457
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06411457 through Pure Global AI's free database. This Phase 2 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Breast Cancer. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.